AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37060448 — intervention group
Group type: EXPERIMENTAL
Intervention: Subventricular zone distance (SVD) measurement from tumor centroid (definition 2)
Number of subjects: 187
Study 37060448 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD-updated survival model
Number of subjects: 187
Study 37060458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dersimelagon (oral selective MC1R agonist)
Number of subjects: 0
Study 37060458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37060545 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose VE303 (8.0 × 10^9 CFUs)
Number of subjects: 79
Study 37060545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose VE303 (1.6 × 10^9 CFUs)
Number of subjects: 79
Study 37060545 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 79
Study 37060708 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated survivors of PFT
Number of subjects: 60
Study 37060708 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-irradiated survivors of PFT
Number of subjects: 60
Study 37060708 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 37060917 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 RVF vaccine (5 × 10^10 viral particles)
Number of subjects: 15
Study 37060934 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sexual debut (<15 years)
Number of subjects: 6079
Study 37060934 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 6079
Study 37060934 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation of sexual intercourse
Number of subjects: 6079
Study 37061109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC) 150 mg once daily for 12 months
Number of subjects: 1778
Study 37061109 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 12 months
Number of subjects: 1778
Study 37061137 — intervention group
Group type: EXPERIMENTAL
Intervention: OverStitch Sx
Number of subjects: 33
Study 37061169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CADe (GI-Genius; Medtronic) and Endocuff Vision (ECV; Olympus)
Number of subjects: 1316
Study 37061169 — intervention group
Group type: COMPARATOR
Intervention: Control group (CADe-assisted colonoscopy alone)
Number of subjects: 1316
Study 37061234 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 371
Study 37061234 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN monotherapy
Number of subjects: 371
Study 37061234 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 371
Study 37060915 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once daily for 5 days)
Number of subjects: 1272
Study 37060915 — intervention group
Group type: COMPARATOR
Intervention: Usual care (including low-dose corticosteroids 6 mg once daily for 10 days)
Number of subjects: 1272
Study 37060915 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose corticosteroids
Number of subjects: 1272
Study 37060915 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1272
Study 37061361 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training during neoadjuvant chemoradiation therapy
Number of subjects: 36
Study 37061361 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised moderate-to-vigorous exercise after therapy
Number of subjects: 36
Study 37061361 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 37061619 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg IV, Q3weeks × 4) and nab-paclitaxel (100 mg/m2)
Number of subjects: 37
Study 37061619 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 37
Study 37061656 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily
Number of subjects: 125
Study 37061656 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 125
Study 37061656 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF/DMF
Number of subjects: 125
Study 37061656 — intervention group
Group type: COMPARATOR
Intervention: PBO/DMF
Number of subjects: 125
Study 37061656 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF/DMF and PBO/DMF
Number of subjects: 125
Study 37061690 — intervention group
Group type: EXPERIMENTAL
Intervention: CDM test results
Number of subjects: 236
Study 37061690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDM test)
Number of subjects: 236
Study 37061693 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) with donor fresh frozen plasma (1.2 × individual plasma volume) performed within 6 hours after randomization.
Number of subjects: 274
Study 37061693 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) control arm.
Number of subjects: 274
Study 37061693 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 274
Study 37061715 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive supervised exercise program (CSEP) consisting of a 12-week intensive phase with 3 exercise sessions of 1 hour per week, followed by a maintenance phase with home exercises and monthly tele-consultations with a physiotherapist.
Number of subjects: 0
Study 37061715 — intervention group
Group type: COMPARATOR
Intervention: Usual supportive care (control group).
Number of subjects: 0
Study 37061794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-assisted, home-delivered, DASH-patterned groceries
Number of subjects: 176
Study 37061794 — intervention group
Group type: COMPARATOR
Intervention: $500 monthly stipend
Number of subjects: 176
Study 37061797 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-to-Clinic Linkage Implementation Program (CLIP) with Barbershop Facilitation (BF) strategy
Number of subjects: 420
Study 37061797 — intervention group
Group type: COMPARATOR
Intervention: Community-to-Clinic Linkage Implementation Program (CLIP) without Barbershop Facilitation (BF) strategy
Number of subjects: 420
Study 37061796 — intervention group
Group type: EXPERIMENTAL
Intervention: LINKED-BP Program (home BP monitoring, BP telemonitoring through the Sphygmo app, CHW telehealth visits for education and counseling on lifestyle modification over 12 months)
Number of subjects: 600
Study 37061796 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 600
Study 37061802 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with an implantable loop recorder (ILR) and initiation of anticoagulation upon detection of AF episodes lasting ≥6 minutes
Number of subjects: 5819
Study 37061802 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 5819
Study 37061802 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with ILR for participants with NT-proBNP above median
Number of subjects: 5819
Study 37061802 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) for participants with NT-proBNP above median
Number of subjects: 5819
Study 37061810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 10 or 30 µg daily
Number of subjects: 813
Study 37061829 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight loss (PPWL) intervention (PPWL-only and GWG+PPWL conditions)
Number of subjects: 430
Study 37061829 — intervention group
Group type: COMPARATOR
Intervention: Gestational weight gain only (GWG-only) intervention
Number of subjects: 430
Study 37062047 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable-polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 2361
Study 37062047 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stent (DP-EES)
Number of subjects: 2361
Study 37062047 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher atherothrombotic risk (H-ATR)
Number of subjects: 2361
Study 37062047 — intervention group
Group type: COMPARATOR
Intervention: Lower atherothrombotic risk (L-ATR)
Number of subjects: 2361
Study 37062298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg + 50 mg
Number of subjects: 718
Study 37062298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg + 30 mg
Number of subjects: 718
Study 37062298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 50 mg
Number of subjects: 718
Study 37062298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg
Number of subjects: 718
Study 37062298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 37062304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+1 PCV10
Number of subjects: 2501
Study 37062304 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+1 PCV13
Number of subjects: 2501
Study 37062304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0+1 PCV10
Number of subjects: 2501
Study 37062304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0+1 PCV13
Number of subjects: 2501
Study 37062304 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2501
Study 37062349 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP therapy with lifestyle counseling
Number of subjects: 184
Study 37062349 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling alone
Number of subjects: 184
Study 37062359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-UFA diet (MUFAs and/or PUFAs)
Number of subjects: 113
Study 37062359 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs) diet
Number of subjects: 113
Study 37062422 — intervention group
Group type: EXPERIMENTAL
Intervention: TG103 3 mg
Number of subjects: 32
Study 37062422 — intervention group
Group type: EXPERIMENTAL
Intervention: TG103 7.5 mg
Number of subjects: 32
Study 37062422 — intervention group
Group type: EXPERIMENTAL
Intervention: TG103 15 mg
Number of subjects: 32
Study 37062422 — intervention group
Group type: EXPERIMENTAL
Intervention: TG103 22.5 mg
Number of subjects: 32
Study 37062422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 37062500 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line anti-TNF therapy
Number of subjects: 185
Study 37062579 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma by association
Number of subjects: 0
Study 37062579 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's gender, biological relatedness, household composition, and family cohesion
Number of subjects: 0
Study 37062581 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG delivered via parent peers (MFG-PP)
Number of subjects: 636
Study 37062581 — intervention group
Group type: EXPERIMENTAL
Intervention: MFG delivered via community healthcare workers (MFG-CHW)
Number of subjects: 636
Study 37062581 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 636
Study 37062580 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple family group intervention (16-week manualized intervention)
Number of subjects: 317
Study 37062580 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple family group intervention
Number of subjects: 317
Study 37062582 — intervention group
Group type: EXPERIMENTAL
Intervention: YDA + MFG
Number of subjects: 1260
Study 37062582 — intervention group
Group type: EXPERIMENTAL
Intervention: YDA
Number of subjects: 1260
Study 37062582 — intervention group
Group type: COMPARATOR
Intervention: BSOC
Number of subjects: 1260
Study 37062584 — intervention group
Group type: EXPERIMENTAL
Intervention: Family economic empowerment intervention (Suubi-Maka)
Number of subjects: 346
Study 37062584 — intervention group
Group type: COMPARATOR
Intervention: Bolstered usual care (control)
Number of subjects: 346
Study 37062658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual immuno-oncology agents (IO+IO)
Number of subjects: 675
Study 37062658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of immuno-oncology drug and a tyrosine kinase inhibitor (TKI)
Number of subjects: 675
Study 37062658 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 675
Study 37062804 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 5
Study 37062834 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention for six months
Number of subjects: 180
Study 37062834 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 180
Study 37062834 — intervention group
Group type: COMPARATOR
Intervention: Metformin (open-label)
Number of subjects: 180
Study 37062953 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet combination of cabozantinib, nivolumab, and ipilimumab
Number of subjects: 0
Study 37062953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab plus lenvatinib plus belzutifan
Number of subjects: 0
Study 37062953 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet combination therapy with immune checkpoint inhibitors or immune checkpoint and tyrosine kinase inhibitor
Number of subjects: 0
Study 37063238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine (Janssen/Johnson & Johnson), single dose
Number of subjects: 477234
Study 37063316 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartFeeding4Kids program (online self-guided intervention for parents)
Number of subjects: 89
Study 37063373 — intervention group
Group type: EXPERIMENTAL
Intervention: Program Sustainability Action Planning Model and Training Curricula
Number of subjects: 11
Study 37063543 — intervention group
Group type: EXPERIMENTAL
Intervention: i-CBT program (self-guided application)
Number of subjects: 41
Study 37063762 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage (LAA)
Number of subjects: 47
Study 37063762 — intervention group
Group type: COMPARATOR
Intervention: Left Atrium (LA)
Number of subjects: 47
Study 37063904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreas transplant alone (PTA)
Number of subjects: 32
Study 37063904 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous pancreas-kidney (SPK)
Number of subjects: 32
Study 37063904 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA with early graft thrombosis
Number of subjects: 32
Study 37063904 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA without early graft thrombosis
Number of subjects: 32
Study 37063916 — intervention group
Group type: EXPERIMENTAL
Intervention: Humoral and cellular immune responses in vaccinated individuals with breakthrough infection
Number of subjects: 0
Study 37063916 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective cell-mediated immunity to SARS-CoV-2
Number of subjects: 0
Study 37063970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study 37063970 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor-based 12-month DAPT
Number of subjects: 0
Study 37063970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT
Number of subjects: 0
Study 37063970 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 0
Study 37064032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 37064032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37064105 — intervention group
Group type: EXPERIMENTAL
Intervention: Right thoracoabdominal surgical approach (RTA)
Number of subjects: 212
Study 37064105 — intervention group
Group type: COMPARATOR
Intervention: Abdominal-transhiatal surgical approach (TH)
Number of subjects: 212
Study 37064508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary counselling (target sodium intake <2.3 g/day)
Number of subjects: 373
Study 37064508 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 373
Study 37065441 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational strategies used by trained conversation moderators
Number of subjects: 0
Study 37065894 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for Awareness, Resilience and Action (TARA)
Number of subjects: 35
Study 37065899 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (Epidiolex®) 600 mg
Number of subjects: 10
Study 37066150 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM-AC intervention (manualized, skills-based training program with four 30-60 minute sessions, facilitated family meeting, smartphone app, and advance care planning module)
Number of subjects: 144
Study 37066150 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM-AC intervention
Number of subjects: 144
Study 37066150 — intervention group
Group type: COMPARATOR
Intervention: Control (usual, non-directive, supportive care without PRISM-AC)
Number of subjects: 144
Study 37066198 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatments for RA
Number of subjects: 106
Study 37066198 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions targeting negative emotions
Number of subjects: 106
Study 37066217 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS (direct current)
Number of subjects: 6
Study 37066217 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tACS (alternating current)
Number of subjects: 6
Study 37066217 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcomes
Number of subjects: 6
Study 37066217 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 6
Study 37066249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily for four doses
Number of subjects: 10
Study 37066249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 10
Study 37066256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored information multimedia app with text at one of three grade levels
Number of subjects: 0
Study 37066256 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37066486 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain voxel-based morphometry and lesional MRI analyses
Number of subjects: 25
Study 37066486 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 37066690 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 167
Study 37066690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 37066788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear imaging screening for cardiac amyloidosis
Number of subjects: 0
Study 37066828 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC-15L treatment group
Number of subjects: 135
Study 37066828 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 135
Study 37066863 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of Fonseca Anamnestic Index (FAI/T)
Number of subjects: 249
Study 37067031 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging-derived measures from the UK Biobank dataset
Number of subjects: 2314
Study 37067193 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 (S3) outflow at Evolut node 4
Number of subjects: 204
Study 37067193 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 (S3) outflow at Evolut node 6
Number of subjects: 204
Study 37067193 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 204
Study 37067353 — intervention group
Group type: EXPERIMENTAL
Intervention: t:slim X2 Insulin Pump with Control-IQ Technology
Number of subjects: 0
Study 37067525 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors (PARPis)
Number of subjects: 54
Study 37067525 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent chemotherapy after PARPis
Number of subjects: 54
Study 37067554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 11
Study 37067675 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA electroporated HBV-specific TCR T cells
Number of subjects: 6
Study 37067785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance-guided fluid management
Number of subjects: 110
Study 37067785 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 37067881 — intervention group
Group type: EXPERIMENTAL
Intervention: PMRT via Zoom and GI exposure
Number of subjects: 108
Study 37067881 — intervention group
Group type: EXPERIMENTAL
Intervention: PMRT via Zoom and personalized VR exposure
Number of subjects: 108
Study 37067881 — intervention group
Group type: EXPERIMENTAL
Intervention: PMRT based on audio-track guidance and personalized VR exposure
Number of subjects: 108
Study 37067896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Savvy program
Number of subjects: 153
Study 37067952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab monotherapy
Number of subjects: 88
Study 37068115 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe dengue (SD)
Number of subjects: 163
Study 37068115 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from first symptom to hospital consultation over 2 days
Number of subjects: 163
Study 37068115 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cardiovascular disease
Number of subjects: 163
Study 37068115 — intervention group
Group type: EXPERIMENTAL
Intervention: Being of Western European origin
Number of subjects: 163
Study 37068272 — intervention group
Group type: EXPERIMENTAL
Intervention: Amubarvimab plus romlusevimab
Number of subjects: 807
Study 37068272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 807
Study 37068273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluvoxamine (100 mg twice daily for 10 days) plus inhaled budesonide (800 mcg twice daily for 10 days)
Number of subjects: 738
Study 37068273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 738
Study 37068366 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating cannabis use pattern
Number of subjects: 149
Study 37068366 — intervention group
Group type: COMPARATOR
Intervention: Low or no cannabis use pattern
Number of subjects: 149
Study 37068366 — intervention group
Group type: COMPARATOR
Intervention: Medium stable cannabis use pattern
Number of subjects: 149
Study 37068366 — intervention group
Group type: COMPARATOR
Intervention: High stable cannabis use pattern
Number of subjects: 149